Antihemophilic factor (recombinant), pegylated LA is a Recombinant Protein owned by Novo Nordisk, and is involved in 12 clinical trials, of which 7 were completed, 4 are ongoing, and 1 is planned.

Turoctocog alfa pegol (N8-GP) acts as a FVIII replacement. Activation of factor VIII results in increase in the catalytic efficiency of factor IXa leading to activation of factor X. FVIII participates as a cofactor in the second burst of thrombin generation, which leads to clot formation.

The revenue for Antihemophilic factor (recombinant), pegylated LA is expected to reach a total of $8.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Antihemophilic factor (recombinant), pegylated LA NPV Report.

Antihemophilic factor (recombinant), pegylated LA is currently owned by Novo Nordisk.

Antihemophilic factor (recombinant), pegylated LA Overview

Antihemophilic factor (recombinant), pegylated (Esperoct) is a long acting recombinant analogue of human coagulation factor VIII (FVIII), acts as an antihemophilic agent. Human factor VIII, produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) cells line culture. It is formulated as lyophilized powder for solution for intravenous route of administration. Esperoct is indicated for use in adults and children with haemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, perioperative management of bleeding.

Turoctocog alfa pegol (N8-GP) is under development for the treatment and prevention of hemophilia A in China. It is administered through intravenous route as bolus.

Novo Nordisk Overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

The company reported revenues of (Danish Krone) DKK140,800 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 41.7%, compared to an operating margin of 42.6% in FY2020. In FY2021, the company recorded a net margin of 33.9%, compared to a net margin of 33.2% in FY2020. The company reported revenues of DKK45,566 million for the third quarter ended September 2022, an increase of 10.4% over the previous quarter.

Quick View – Antihemophilic factor (recombinant), pegylated LA

Report Segments
  • Innovator (NME)
Drug Name
  • Antihemophilic factor (recombinant), pegylated LA
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.